0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Effects of Mytatrienediol in Multiple Myeloma, Metastatic Bone Disease, and Osteoporosis

BERNARD KABAKOW, M.D.; HERTA SPENCER, M.D.
AMA Arch Intern Med. 1960;105(6):905-913. doi:10.1001/archinte.1960.00270180083011.
Text Size: A A A
Published online

Multiple myeloma mainly affects the skeleton and may cause marked derangement of mineral metabolism. Hypercalciuria is frequently present and hypercalcemia may be a very serious, and at times fatal, complication of the disease. Estrogens have been shown to decrease urinary calcium excretion 1 and to relieve bone pain in metastatic bone disease2 and in osteoporosis.3,4 In the study of the metabolic effects of newer synthetic hormones, it was found that a weak estrogenic compound, 3-methoxy-16α-methyl-1,3,5 (10)-estratriene-16β, 17β-diol, Mytatrienediol, is effective in decreasing urinary calcium excretion, and the incidental observation of relief of bone pain was made in a patient with multiple myeloma.5 The effect of this hormone was further investigated in a larger number of patients afflicted with this disease, especially in regard to relief of bone pain and to changes of urinary calcium excretion. This hormone was also administered to patients with metastatic bone disease caused

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 5

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();